Gemfibrozil treatment of combined hyperlipoproteinemia: No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 4, 1996, Pages 511-516

  Bröijersen, Anders ^a   Eriksson, Mats ^b   Wiman, Björn ^a   Angelin, Bo ^b   Hjemdahl, Paul ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

fibrinolysis; gemfibrozil; hyperlipoproteinemia; plasminogen activator inhibitor; tissue type plasminogen activator

Indexed keywords

GEMFIBROZIL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FIBRINOLYSIS; HUMAN; HYPERLIPOPROTEINEMIA; MALE; MENTAL STRESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROVOCATION TEST; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VEIN OCCLUSION;

EID: 0029871877     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.4.511     Document Type: Article

References (32)

1. Wiman B, Hamsten A. Decreased fibrinolytic activity in thrombotic disease: an update. In: Samama MM. Seghatchian MJ, eds. Hypercoagulable States: Biological Aspects and Clinical Management. Boca Raton, Fia: CRC Press: In press.
2. Simpson HCR, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet. 1983;1786-789.
3. Andersen P, Arnesen H, Hjermann I. Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand. 1981;209:199-202.
4. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 1992;12:19-27.
5. Frick MH, Elo O, Happa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-age men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
6. Fujii S, Sawa H, Sobel BE. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb Haemost. 1993;70:642-647.
7. Avellone G, Di Garbo V, Panno AV, Cordova R, Lepore R, Strano A. Changes induced by gemfibrozil on lipidic, coagulative and fibrinolytic pattern in patients with type IV hyperlipoproteinemia. Int Angiol. 1988;7:270-277.
8. Avellone G, Di Garbo V, Cordova R, Ranelli G, De Simone R, Bompiani GD. Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia. Curr Ther Res. 1992;52:338-348.
9. Avellone G, Di Garbo V, Cordova R, Panno AV, Ranelli G, De Simone R, Bompiani GD. Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion. Fibrinolysis. 1993;7:416-421.
10. Andersen P, Smith P, Scljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost. 1990;63:174-177.
11. Keber I, Lavre J, Sue S, Keber D. The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates. Fibrinolysis. 1994;8:57-59.
12. Frankenhaeuser M, Mellis I, Rissler A, Björkvall C, Patkai P. Catecholamine excretion as related to cognitive and emotional reaction patterns. Psychosom Med. 1968;30:109-120.
13. Vermylen C, de Vreker R, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chim Acta. 1963;8:418-424.
14. Carlsson K. Lipoprotein fractionation. J Clin Pathol. 1973;26(suppl 5):32-37.
15. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem. 1977;23:882-884.
16. Hjemdahl P. Catecholamine measurements in plasma by high-performance liquid chromatography with electrical detection. Methods Enzymol. 1987;142:521-534.
17. Jones B, Kenward MG. Design and Analysis of Cross-over Trials. New York, NY: Chapman and Hall; 1989.
18. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
19. Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ. 1985;291:573-574.
20. Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
21. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M, for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. Arterioscler Thromb. 1993;13:1412-1417.
22. Haire WD. Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis. Thromb Res. 1991;64:493-501.
23. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud M, Atlan C. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabetes Metab. 1987;13:331-336.
24. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and scrum triglyceride concentrations. J Am Coll Cardiol. 1987;9:263-268.
25. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost. 1987;57:326-328.
26. Sundell IB, Dahlgren S, Rånby M, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis. 1989;3:51-53.
27. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
28. Juhan-Vague I, Thompson SG, Jespersen J, for the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome, a study of 15 000 patients with angina pectoris. Arterioscler Thromb. 1993;13:1865-1877.
29. Elkeles RS, Chakrabarti R, Vickers M, Stirling Y, Meade T. Effect of treatment of hyperlipidaemia on haemostatic variables. BMJ. 1980;281:973-974.
30. Andersen P, Nilsen DWT, Lyberg Beckman S, Holme I, Hjermann I. Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals. Ada Med Scand. 1988;223:499-506.
31. Wiklund O, Angelin B, Olofsson S-O, Eriksson M, Fager G, Bcrglund L, Bondjers G. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet. 1990;335:1360-1363.
32. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.